"PPAR delta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nuclear transcription factor. It is activated by PROSTACYCLIN.
| Descriptor ID |
D047494
|
| MeSH Number(s) |
D12.776.826.239.555
|
| Concept/Terms |
PPAR delta- PPAR delta
- PPARdelta
- Peroxisome Proliferator-Activated Receptor delta
- Peroxisome Proliferator Activated Receptor delta
- PPARD protein
|
Below are MeSH descriptors whose meaning is more general than "PPAR delta".
Below are MeSH descriptors whose meaning is more specific than "PPAR delta".
This graph shows the total number of publications written about "PPAR delta" by people in this website by year, and whether "PPAR delta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "PPAR delta" by people in Profiles.
-
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):783-794.
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):795-805.
-
Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis. Pathology. 2022 Oct; 54(6):686-693.
-
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
-
Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 10; 2(10):716-726.
-
Molecular biology of endometriosis: from aromatase to genomic abnormalities. Semin Reprod Med. 2015 May; 33(3):220-4.
-
HIV-1 Vpr enhances PPAR?/d-mediated transcription, increases PDK4 expression, and reduces PDC activity. Mol Endocrinol. 2013 Sep; 27(9):1564-76.
-
A comprehensive nuclear receptor network for breast cancer cells. Cell Rep. 2013 Feb 21; 3(2):538-51.
-
Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPARdelta/PGE2 and elevation of PGE3. Carcinogenesis. 2008 Apr; 29(4):790-6.
-
Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene. 2006 Feb 23; 25(8):1225-41.